SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel tumor ablation therapy, announced today that the US Patent and Trademark Office has issued to Genetronics, Inc., Inovio’s wholly-owned subsidiary, US Patent number 7,171,264, titled “Intradermal Delivery of Active Agents by Needle-Free Injection and Electroporation.”
